Physicians' Academy for Cardiovascular Education

Antidrug antibodies against PCSK9 antibody did not affect efficacy and safety

Antidrug Antibodies in Patients Treated with Alirocumab

Letter to the editor

Literature - Roth EM, Goldberg AC, Catapano AL, et al. - NEJM 2017, Epub ahead of print

Main results

Conclusion

Although antidrug antibodies were present in some patients treated with alirocumab, this did not affect the magnitude and duration of LDL-lowering. However, it should be noted that the number of patients with immunogenicity was very small.

References

Show references

Find this letter online at NEJM

Share this page with your colleagues and friends: